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Background: The extracellular domain of matrix protein 2 (M2e) of influenza A virus is a promising target for the
development of a universal vaccine against influenza because M2e sequences are highly conserved among human
influenza A strains. However, native M2e is poorly immunogenic, but its immunogenicity can be increased by delivery in
combination with adjuvants or carrier particles. It was previously shown that fusion of M2e to bacterial flagellin, the ligand
for Toll-like receptor (TLR) 5 and powerful mucosal adjuvant, significantly increases the immunogenicity and protective
capacity of M2e.
Results: In this study, we report for the first time the transient expression in plants of a recombinant protein Flg-4M
comprising flagellin of Salmonella typhimurium fused to four tandem copies of the M2e peptide. The chimeric
construct was expressed in Nicotiana benthamiana plants using either the self-replicating potato virus X (PVX)
based vector, pA7248AMV-GFP, or the cowpea mosaic virus (CPMV)-derived expression vector, pEAQ-HT. The
highest expression level up to 30 % of total soluble protein (about 1 mg/g of fresh leaf tissue) was achieved with
the PVX-based expression system. Intranasal immunization of mice with purified Flg-4M protein induced high
levels of M2e-specific serum antibodies and provided protection against lethal challenge with influenza virus.
Conclusions: This study confirms the usefulness of flagellin as a carrier of M2e and its relevance for the
production of M2e-based candidate influenza vaccines in plants.
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Influenza is a widely distributed viral infection of humans
and animals. The high variability of the surface viral pro-
teins, hemagglutinin and neuraminidase, results in the ap-
pearance of a new epidemic strain every one to two years
[1]; this requires the production of new vaccines at the
same frequency. A promising solution to this problem is
the development of recombinant vaccines that can be rap-
idly produced in standard expression systems. One of the
most promising conserved antigens of influenza virus is* Correspondence: nravin@biengi.ac.ru
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unless otherwise stated.the extracellular domain of transmembrane protein M2,
M2e [2]. The length of M2e is only 24 amino acid residues
(including the initiator methionine). Its sequence is virtu-
ally unchanged in all human isolates since 1933 [3–5], and
in strains of avian influenza A it differs in only a few
amino acids. By itself M2e possesses low immunogenicity
[6] but this can be increased by delivery in a multimeric
form or in combination with complex adjuvants or deliv-
ery systems [3, 5, 7–9].
Toll-like receptors (TLRs) have been shown to play a
critical role in controlling the adaptive immune response,
by properly arming dendritic and other antigen-presenting
cells, triggering important costimulatory and regulatory
mechanisms, and promoting antigen presentation [10, 11].tral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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antigen of interest to bacterial flagellin, the ligand for
TLR5, significantly increases the immunogenicity and
protective capacity of the antigen [12, 13]. Notably fla-
gellin is particularly active as mucosal adjuvant, opening
the possibility of non-invasive intranasal administration
of vaccines. The ability of flagellin to be both the plat-
form and the adjuvant for different vaccines was dem-
onstrated in various models of infection including
influenza [13–19].
Recombinant proteins, including those for medical
purposes, can be produced in a variety of expression
systems, including bacteria, yeast, plants, and mamma-
lian cells. The advantages of using plants for protein
production include the low final cost and inherent
safety of products due to the absence of pathogens com-
mon for plants and animals. Recombinant proteins in
plants may be obtained by stable genetic transformation
(either nuclear or plastid) or through transient expres-
sion [20–22]. Creation of lines of stably transformed
plants and, subsequently, production of a protein from
such plants requires considerable time and cost. The
level of expression of target proteins by transgenic
plants is usually relatively low, resulting in a high cost of
products due to the difficulty of their purification [23,
24]. The use of self-replicating viral vectors or efficient
non-replicating transient expression vectors is an alter-
native approach providing sufficient amounts of the de-
sired protein (up to 1–2 g/kg of plant biomass) [20] to
conduct immunological studies. To create such vectors,
sequences from tobacco mosaic virus (TMV), cowpea
mosaic virus (CPMV) or potato virus X (PVX) have fre-
quently been used. The genomes of these viruses are
small and consist of positive-strand RNA. The vectors
are introduced into plant cells by infiltration of the plant
leaf tissue with Agrobacterium suspensions carrying the
vector within the T-DNA portion of a binary plasmid
resulting in transfer of vector DNA into the recipient plant
cells during the agroinfection [25, 26]. Such expression sys-
tems have been used for production of a variety of pharma-
ceutical proteins, including antibodies and candidate
vaccines [22, 27, 28]. The latter have included influenza
virus hemagglutinin [29–31] and HBc virus-like particles
carrying M2e peptide [9].
In this work four tandem copies of M2e sequences
based on human and avian influenza virus isolates were
genetically fused to Salmonella typhimurium flagellin
and produced in Nicotiana benthamiana plants using
transient expression using either a replicating PVX vec-
tor [32] or the non-replicating CPMV-HT system [33,
34]. Intranasal immunization of mice with the plant-
produced hybrid protein induced the desired immune
response and conferred protective immunity against a
lethal influenza virus challenge.Results
Viral vectors for expression of the hybrid protein
consisting of flagellin linked to four copies of influenza
M2e peptide in N. benthamiana plants
The highly conserved extracellular domain of the influ-
enza virus M2 protein, M2e, is a promising target for
the development of recombinant “universal” vaccines
against influenza [5]. However, M2e is poorly immuno-
genic and needs to be presented in a multimeric form or
linked to a carrier molecule such as virus-like particles
[3]. Here we use flagellin of Salmonella typhimurium as
such carrier and simultaneously as an adjuvant. In order
to make a broader range candidate vaccine, a hybrid pro-
tein Flg-4M containing two copies of human consensus
M2e sequence and two copies of the M2e peptide of avian
influenza virus strain A/Chicken/Kurgan/05/2005 fused to
the C-terminus of S. typhimurium FljB (arranged as Flg-
M2eh-M2ek-M2eh-M2ek) was designed. In order to facili-
tate folding of hybrid protein, copies of M2e peptides were
separated from each other by flexible glycine-rich linker
(Fig. 1a). The empty flagellin (lacking M2e) was used as a
control. Both proteins, Flg-4M and Flg, were designed with
N-terminal 6-histidine tag to facilitate their purification.
Two plant virus-based transient expression systems were
used for production of recombinant Flg-4M protein in N.
benthamiana. The first vector, pA7248AMV-GFP [32], is a
replicating system based on the PVX genome. This vector
includes the 5’-UTR of the PVX genome, the polymerase
gene, the first promoter of subgenomic RNA, the translation
enhancer represented by the sequence of the 5’-untranslated
region of RNA 4 of the alfalfa mosaic virus (AMV), the GFP
gene flanked by unique restriction sites AscI and SmaI, the
last 60 nucleotides of the coat protein gene, and the 3’-
untranslated region of the PVX genome. This construction
is nserted between the 35S promoter and 35S terminator
and cloned in the binary vector pBIN19 [32]. To create
the viral vector allowing production of the Flg-4M
protein, a sequence of the hybrid gene was cloned in
pA7248AMV-GFP at the AscI and SmaI sites to replace
GFP, which resulted in construction of a recombinant vec-
tor pA7248AMV-Flg-4M (Fig. 1b). Recombinant vector
pA7248AMV-Flg for expression of Flg in plants was con-
structed in a similar way.
The second expression system, pEAQ, is based on CPMV.
This is a non-replicating system which uses production of a
highly translatable mRNA to achieve high level expression.
The recombinant vector pEAQ-Flg-4M contains 5’-UTR
and 3’-UTR from CPMV RNA-2 upstream and down-
stream, respectively, of the hybrid gene Flg-4M (Fig. 1b).
Expression of the hybrid protein Flg-4M in N.
benthamiana plants
To express the protein Flg-4M, vectors were inserted
into A. tumefaciens strain GV3101, which was used for
Fig. 1 Structure of the expression constructs used in this study. a Amino acid sequence of Flg-4M protein. The sequences of human “consensus” M2e
peptides, M2eh, are italicized; the sequences of M2e peptide of avian influenza virus strain A/Chicken/Kurgan/05/2005, M2ek, are shown in bold; the
linker sequences are underlined. Flagellin sequence is shaded in grey. b Structures of viral vectors pA7248AMV-Flg-4M and pEAQ-Flg-4M. The tDNA
regions of the binary vectors are shown. RDRP, RNA dependent RNA polymerase of PVX; Sgp1, subgenomic promoter of the PVX protein 25 K; AMV,
the leader sequence of RNA 4 of the alfalfa mosaic virus; 6his, 6 histidine tag; FLG, flagellin of S. typhimurium; 4M2e, four copies of M2e peptide
(arranged as M2eh-M2ek-M2eh-M2ek); 35S, promoter; 35S-T, terminator of the cauliflower mosaic virus RNA; NosT, terminator of nopaline synthase
gene; LB and RB are the left and right borders of tDNA; p19, gene of silencing suppressor P19 from the tomato bushy stunt virus; 5’ and 3’, the 5’-UTR
and the 3’-UTR from PVX (in pA7248AMV-Flg-4M) and CPMV (in pEAQ-Flg-4M)
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Agroinfiltration zones for two vectors were located
within one leaf. Protein samples were isolated in 3, 4, 5,
6, and 7 days after infection. For every day three leaves
were taken for analysis. Protein samples were analyzed
using SDS-PAGE and western-blotting (Fig. 2). Maximal
expression was observed at fourth day. Summarizing the
expression results for 15 leaves we found out that
pEAQ-Flg-4M construct provides expression level of
about 30 % in comparison to pA7248AMV-Flg-4M.
Given the higher levels of expression obtained, we used
vector pA7248AMV-Flg-4M for the scaled-up production
of protein Flg-4M in N. benthamiana plants. The total
soluble protein was isolated from leaves at 4th day after
agroinfiltration and analyzed by SDS-PAGE. The data pre-
sented in Fig. 3a show that Flg-4M protein is highly
expressed and accounted for about 30 % of the soluble
protein fraction (~1 mg/g of fresh leaf tissue). The
recombinant protein was specifically revealed in western
blot analysis with the monoclonal antibodies specific toM2e (Fig. 3b). The recombinant fusion protein carrying an
N-terminal 6-histidine tag was purified to a purity of greater
than 90 % (Fig. 3a) using standard affinity chromatography
on Ni-NTA resin and used for animal experiments. The re-
combinant Flg protein was expressed in N. benthamiana
using vector pA7248AMV-Flg and purified in a similar way.
Antigenicity of plant-produced protein Flg-4M
The display of the M2e peptide in an accessible manner
when it is fused with flagellin in the Flg-4M protein was
examined by ELISA. To this end plates were coated with
serial dilutions of Flg-4M protein and empty Flg, then
probed with the M2e-specific and the 6-his tag-specific
monoclonal antibodies (Fig. 4). While both Flg-4M and
Flg reacted with the anti-his antibodies, only Flg-4M
reacted with the M2e-specific antibodies. These results
confirm the presence of M2e in the purified Flg-4M
protein and its accessibility for antibodies.
The M2e peptides naturally exposed on the surface of
infected cells as tetramers tends to aggregate due to the
Fig. 2 Efficiency of PVX- and CPMV-based vectors. Coomassie brilliant blue stained gel (a) and western blot (b) of proteins isolated form N.
benthamiana plants and separated by SDS-PAGE. M, − molecular weight marker (kD); 1 and 2, − total soluble proteins isolated at fourth day after
agroinfiltration from leaves infiltrated with vector pA7248AMV-Flg-4M and pEAQ-Flg-4M, respectively; 3, − total soluble proteins isolated from
empty leaves. Antibodies against M2e were used in western blotting
Fig. 3 Expression and purification of Flg-4M protein. Coomassie brilliant blue stained gel (a) and western blot (b) of proteins isolated form N. benthamiana
plants and separated by SDS-PAGE. M, −molecular weight marker (kD); 1, − total soluble proteins isolated from empty leaves; 2, − total soluble proteins
isolated at fourth day after agroinfiltration from leaves infiltrated with vector pA7248AMV-Flg-4M; 3, − purified Flg-4M protein. Antibodies against M2e were
used in western blotting
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Fig. 4 Antigenicity of Flg-4M protein. Two-fold dilutions of recombinant Flg-4M or Flg proteins (starting from 30 μg/ml) were coated on ELISA
plates which were then probed with monoclonal antibodies specific for M2e (a) or 6-his tag present both in Flg-4M and Flg (b)
Fig. 5 Titers of IgG antibodies to synthetic M2e peptides G-50 and G-37
in sera of immunized mice. The data obtained in two independent
experiments after the second and the third immunizations are shown.
The results are expressed as the mean titer ± standard deviation for each
group of five mice. Titers lower than 200 were detected for mice
immunized with PBS or Flg
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to disulfide bond formation and intra- and interprotein
cross-linking. In order to control the lack of aggregation
of Flg-4M protein we also performed western-blot ana-
lysis of purified protein under reducing and non-
reducing conditions. The recombinant protein migrated
at expected position and was revealed by the monoclonal
antibodies specific to M2e, suggesting the lack of aggre-
gation (see Additional file 1). No high-molecular weight
aggregates or particulate structures were detected by the
electron microscopy of purified protein samples.
Immunogenicity and protectivity of plant-produced
protein Flg-4M
To characterize the immunogenicity and protective action,
we performed two sets of animal experiments. In the first
case mice were immunized with the plant-produced prep-
aration of Flg-4M protein, in the second experiment an
additional group of mice was immunised with plant-
produced flagellin lacking M2e. Mice were vaccinated in-
tranasally three times at two-week intervals with 10 μg
protein without additional adjuvants. Blood samples were
taken 2 weeks after the second and/or third immuniza-
tions. Serum was analysed by ELISA to identify IgG anti-
bodies directed against M2e, using plates coated with
synthetic peptides G-37 and G-50, whose sequences cor-
responded to the human “consensus” M2e sequence and
the M2e of influenza strain A/Chicken/Kurgan/05/2005,
respectively. A strong immune response was activated
after the second immunisation and further increased after
the third (Fig. 5). Induced antibodies efficiently bind to
both synthetic M2e peptides G-50 and G-37, which are
present in the candidate vaccine, although the immune
response towards G37, the human M2e sequence, was
stronger.
In the first experiment the immunised and control mice
were challenged with 10LD50 of mouse-adapted human in-
fluenza strain A/PR/8/34 (H1N1) and with 5LD50 of avian
influenza strain A/Chicken/Kurgan/05/2005 (Н5N1). As
shown in Fig. 6a, 75 % mice immunized with Flg-4M,survived the lethal challenge of A/Chicken/Kurgan/05/2005
(Н5N1), while the rate of survival among the control mice
was 14 %. The challenge of immunized mice with 10LD50
of A/PR/8/34 (H1N1) led to a 50 % survival, while all
control mice died upon infection (Fig. 6b).
In the second experiment 5LD50 of influenza strain A/
PR/8/34 (H1N1) was used for challenge. Figure 6c shows
that mice immunised with Flg-4M were completely
protected from lethal virus challenge, while mice
immunised with Flg or PBS were not protected. The
morbidity of the disease was monitored by measuring
the weight of the animals. The data presented in Fig. 6d
reveal that immunisation did not eliminate morbidity
but reduced it relative to the control.
Discussion
The purpose of the present work was to develop a plant-
produced candidate influenza vaccine based on M2e
Fig. 6 Protective efficiency of the plant-produced Flg-4M protein. Experiment 1: mice were challenged with 5LD50 of A/Chicken/Kurgan/05/2005
(a) or with 10LD50 of A/PR/8/34 (b). Experiment 2: mice were challenged with 5LD50 of influenza strain A/PR/8/34 (c, d). Survival (a, b, c) and
weight (d) of immunized and control mice were monitored for 14 days post-challenge. Control, mice immunized with PBS
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for mucosal immunization. It was previously demon-
strated [13] that immunization of mice with E. coli-pro-
duced flagellin linked to four tandem copies of human
“consensus” M2e, provides protection against lethal chal-
lenge with human influenza A strain. Although the M2e
sequence is well conserved in almost all influenza strains
isolated from humans, the sequences of M2e peptides of
newly emerging highly pathogenic strains of animal origin,
such as avian influenza, differ from the human consensus,
suggesting that a specific M2e-based vaccine against these
strains would be required [35]. Combination of several
M2e peptides of different origin in one vaccine protein
could allow development of candidate vaccine efficient
against the corresponding strains [36]. Therefore in
addition to human consensus M2e peptide we included
M2e peptides of avian influenza virus into the hybrid pro-
tein based on bacterial flagellin.
Although plants for a long time have been recognized as
a promising host for expression of recombinant proteins,
including vaccines, there are no universal approaches en-
suring high level expression for any protein of interest.
Here we used two plant viral-based expression system for
production of Flg-4M protein in N. benthamiana. The
first is replicating vector pA7248AMV-GFP based on
PVX genome, and the second vector pEAQ comprising
fragments of CPMV genome is unable to replicate in plant
cell. In this instance the replicating PVX-based vector gave
higher expression of the Flg-4M protein than pEAQ. The
results obtained here are in contrast to those found when
comparing the expression of the Human Papillomavirus
8 L1 protein using a replicating TMV-based vector andthe pEAQ-HT system where the latter gave a 15-fold
higher level [37]. There are several possible explanations
for this difference in expression levels between the two
systems: it may reflect an intrinsic higher level of expres-
sion from the replicating versus the non-replicating sys-
tem or it may relate to the strain of A. tumefaciens
(GV3101 vs LBA4404) used for infiltration. The target
protein was expressed in N. benthamiana cells at very
high level up to 30 % of total soluble protein for
pA7248AMV-GFP (~1 mg/g of fresh leaf tissue). It is
much higher than 280 μg/g of fresh weight leaves reported
for expression of the flagellin alone using non-replicating
transient expression system [38]. Analysis of the plant-
expressed Flg-4M protein by transmission electron
microscopy did not reveal the presence of aggregates. This
coupled with observation that the protein remained in the
supernatant after ultracentrifugation suggests that the
protein remains in an essentially unaggregated state.
Intranasal immunization of mice with the plant-
produced Flg-4M protein induced an immune response
against M2e and was responsible for development of
protective immunity against the lethal influenza infection.
Complete protection was observed in an experiment
where immunized mice were challenged with 5LD50 of
human influenza strain A/PR/8/34. Notably the
protection strongly depended on the presence of M2e
in the hybrid protein, since immunisation with plant-
produced empty Flg confer no extra protection relative
to the negative control. In other experiments the pro-
tection was, however, not 100 % complete that could
be related to low immunization dose (only 10 μg)
and, in case of experiment with 10LD50 of A/PR/8/34
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denced by complete mortality in the control group.
The lack of complete protection of mice was observed
by Stepanova et al. [39] in case of Flg-4M protein
produced in E. coli: 90 % survival upon challenge with
5LD50 of A/Chicken/Kurgan/05/2005 and 80 % survival
upon challenge with 5LD50 of A/PR/8/34 strain,
although a higher dose of vaccine protein, 50 μg, was
used for each of three immunisation.
Three other examples of the plant-based expression of
the M2e epitope have been reported. Ravin et al. [9],
using the PVX-based vector employed in this work, pro-
duced HBc virus-like particles carrying the M2e peptide
with the yield about 1-2 % of total soluble protein; the
plant-produced particles induced a protective immune
response (90 % survival) against 1LD50 of homologous
influenza A infection. Virus-like particles formed by L1
protein of human papillomavirus fused to M2e were
produced in N. benthamiana with the pEAQ-HT expres-
sion system with the yield in the range from 45 to
120 μg/g of fresh weight [40]. Another approach is con-
struction of recombinant tobacco mosaic virus carrying
M2e epitope as a fusion with the coat protein; such vi-
ruses are capable of systemic infection of N. benthami-
ana plants and induced a protective immune response
against challenge with 5LD50 of homologous influenza A
virus [41]. Altogether these results indicated that pro-
duction of M2e-based candidate influenza vaccines in
plants is feasible. The particular advantage of flagellin as
a mucosal adjuvant suggests that expression of flagellin-
M2e hybrid protein in plants by agroinfiltration with a
recombinant viral vectors is a promising approach for
production of recombinant vaccines against influenza.
Conclusions
In this study, we expressed the chimeric protein comprising
flagellin of Salmonella typhimurium fused to four tandem
copies of the influenza M2e peptide in N. benthamiana
plants. The use of self-replicating viral vector based on PVX
genome allowed to achieve very high level of expression up
to 1 mg/g of fresh leaf tissue. Intranasal immunization of
mice with purified vaccine protein induced high levels of
M2e-specific serum antibodies and provided protection
against lethal challenge with influenza virus. This work
shows that expression of fusion proteins based on flagellin
and M2e in plants is feasible and could became a promising
approach for manufacturing of “universal” recombinant vac-
cines against influenza.
Methods
Media, reagents and synthetic gene
Bacteria were grown in LB broth or on plates with LB agar
at 37 °C (Escherichia coli) or at 28 °C (Agrobacterium tume-
faciens). If necessary, the media were supplemented withantibiotics: kanamycin (50 μg/ml), rifampicin (50 μg/ml), or
gentamycin (25 μg/ml). Monoclonal antibodies to the M2e
(clone M2A10) were generously provided by Dr. Peter
Sveshnikov from the Russian Research Center of Molecular
Diagnostics and Therapy.
Previously we constructed an artificial gene Flg-4M
encoding a hybrid protein carrying an N-terminal histidine
tag and consisting of flagellin of Salmonella typhimurium
(Flg) with four copies of M2e peptide linked to its C
terminus [39]. The M2e sequences corresponded to a human
“consensus” M2e peptide (SLLTEVETPIRNEWGCRCNDSS
DP, M2eh), and the M2e peptide of avian influenza virus
strain A/Chicken/Kurgan/05/2005 (SLLTEVETPTRNEWEC
RCSDSSD, M2ek). Individual copies of the M2e peptides
were separated from each other by flexible glycine-rich
linkers. The hybrid gene, arranged as Flg-M2eh-M2ek-
M2eh-M2ek, was cloned in expression vector pQE30 result-
ing in plasmid pQE30_Flg2M2eh2M2ek. The amino acid
sequence of the hybrid protein Flg-4M is shown in Fig. 1a.
Vectors for expression of target proteins in plants
For expression of the hybrid protein Flg-4M in plants the
corresponding gene was cloned into vectors pA7248AMV-
GFP (based on the PVX genome [32]) and pEAQspecialK-
GFP-HT (a non-replicating CPMV-based vector [34]). These
are the binary vectors and can be maintained in both E. coli
and A. tumefaciens. The sequence encoding Flg-4M was
amplified by PCR using primers AscI-Flg-F (ATGGCG
CGCCATGCATCACCATCACCATCACGGA) and M2K-
SmaI-R (ATCCCGGGAATTAAGCTGGGGTACCCTAAT
CG) or NruI-Flg-F (ATTCGCGAATGCATCACCATCAC
CATCACGGA) and M2K-AvaI-R (ATCTCGAGAATTAA
GCTGGGGTACCCTAATCG) using pQE30_Flg2M2eh2-
M2ek as a template for PCR-amplification.
For expression of flagellin lacking M2e (Flg) the corre-
sponding gene was amplified by PCR using primers
AscI-Flg-F (ATGGCGCGCCATGCATCACCATCACCA
TCACGGA) and Flg-SmaI-R (ATCCCGGGCTAACG-
TAACAGAGACAGCACGTTC) and pQE30_Flg2M2eh
2M2ek as a template.
The PCR fragments encoding Flg-4M were cloned in
pA7248AMV-GFP at the AscI/SmaI sites or in pEA
QspecialK-GFP-HT at the NruI/AvaI sites. The resulting
recombinant vectors, pA7248AMV-Flg-4M and pEAQ-
Flg-4M (Fig. 1b), were transferred from E. coli into the
A. tumefaciens strain GV3101 using electroporation.
Likewise the PCR fragment encoding Flg was cloned in
pA7248AMV-GFP at the AscI/SmaI sites resulting in re-
combinant vector pA7248AMV-Flg for expression of 6-
his tagged flagellin in plants.
Agroinfiltration of plants
Agrobacteria carrying recombinant binary vectors were
grown overnight with shaking at 28 °C. The cells (1.5 ml)
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the pellet was resuspended in 1.5 ml of buffer containing
10 mM MES (pH 5.5) and 10 mM MgSO4. Leaves of N.
benthamiana plants were infiltrated with suspension of
agrobacteria (optical absorption of the solution OD600 ~
0.2) using a syringe without a needle.
For expression of pA7248AMV-Flg-4M, the plant leaves
were concurrently infiltrated with agrobacteria carrying
binary vector driving expression of silencing suppressor 24-
kDa protein (p24) from grapevine leafroll-associated virus-2
[42] to suppress virus-induced gene silencing. The same
protocol was used for expression of Flg.
Isolation of proteins from plant tissues
The plant-produced Flg-4M protein carrying 6-histidine
tag was isolated under denaturing conditions on Ni-NTA
Resin (Promega, USA). Four to five days after infiltration,
the N. benthamiana leaves were powdered to homogen-
eity in liquid nitrogen. A solution containing 6 M Guan-
idine HCI, 0.1 M NaH2PO4, 0.01 M Tris (pH 8.0) was
added to the powdered plant tissue (5 mL per 1 g). The
resulting mixture was centrifuged at 14,000 g for 15 min,
and the supernatant was applied to Ni-NTA-resin equili-
brated with the same buffer and incubated for 60 min.
Then the resin was sequentially washed with PBS (50 mM
NaH2PO4, 300 mM NaCI, pH 8.0) buffer containing
10 mM and 20 mM imidazole, respectively. The recom-
binant protein Flg-4M was eluted with PBS containing
0.5 M imidazole. After elution the protein was dialyzed
against PBS using Slide-A-Lyzer Mini dialysis devices
(Thermo Scientific, USA). Dialyzed protein preparation
was centrifuged at 100,000 g to remove Rubisco aggre-
gates and then supernatant was stored at −20 °C in PBS.
Total soluble proteins were measured by a Bradford assay
(Bio-Rad) following manufacturer’s instructions. The same
protocol was used for purification of Flg.
SDS-PAGE and western-blotting of protein preparations
Protein samples were diluted in SDS-PAGE sample buffer
including β-mercaptoethanol. The samples were boiled for
5 min and subjected to SDS-PAGE in a 10 % (w/v) gel.
After electrophoresis, the gel was either stained with Coo-
massie brilliant blue or the proteins were transferred from
the gel onto a Hybond-P membrane (GE Healthcare,
USA) by electroblotting. To prevent nonspecific binding
of antibodies with the membrane, it was treated with 5 %
(w/v) solution of dry milk in TBS-T (150 mM NaCI,
20 mM Tris, 0.1 % Tween 20, pH 8.0) buffer. The mem-
brane was probed with mouse monoclonal antibodies
specific for the M2e peptide and then incubated with
rabbit anti-mouse antibodies conjugated with peroxidase.
Specific protein complexes were detected using a
Western Blot ECL Plus kit (GE Healthcare, USA). The
intensity of the bands in stained gels and blotswas determined using Nonlinear. Dynamics. TotalLab.
TL120.v2009-NULL software.
Western blot analysis of purified Flg-4M under non-
reducing conditions was performed as above but that β-
mercaptoethanol was not included in the sample buffer
and the sample was not boiled before loading onto a gel.
Protein ELISA
To confirm identity and accessibility of M2e to antibodies,
ELISA plates were coated overnight at 4 °C with serial di-
lutions of Flg-4M or Flg proteins in sodium bicarbonate
buffer pH 8.5. Plates were treated with a blocking buffer
supplemented with 0.1 % (w/v) BSA for 2 h at 37 °C and
washed three times using PBS with Tween. Plates were
probed with monoclonal antibody specific for M2e or 6-
His tag for 1 h at 37 °C. As a conjugate, rat monoclonal
anti-mouse IgG (Imtek, Russia) labelled with a horseradish
peroxidase was used at a 1:10,000 dilution. After adding
tetramethylbenzidine substrate (BD Bioscience) and moni-
toring color development, the reaction was stopped by
H2SO4, and OD at 450 nm was measured on a microplate
spectrophotometer.
Synthetic peptides
The following synthetic peptides were tested as a posi-
tive control in the ELISA experiments:
G-50 SLLTEVETPTRNEWECRCSDSSD (M2ek, A/
Chicken/Kurgan/05/2005)
G-37 SLLTEVETPIRNEWGCRCNDSSD (M2eh, hu-
man consensus). Residues that differ between the se-
quences are underlined.
Analysis of production of antibodies against M2e
Female Balb/c mice weighing 18–20 g were immunized
intranasally thrice at two week intervals. The dose of Flg-
4M and Flg proteins was 10 μg/mouse and no additional
adjuvant was used. The mouse sera were studied two
weeks after the second and third immunizations. The sera
of non-immunized mice were used as a negative control.
For ELISA, 96-well plates with a high adsorption cap-
acity (Greiner, Germany) were covered with synthetic pep-
tides G-50 (M2ek) and G-37 (M2eh) at a concentration of
5 mg/ml (w/v) in phosphate buffer, pH 7.2–7.4 and kept
overnight at 4 °C. Plates were treated with a blocking buf-
fer (0.01 M PBS, pH 7.2–7.4) supplemented with 5 % (v/v)
fetal calf serum for 1 h at room temperature and washed
three times using PBS with Tween. A series of 1:2 dilu-
tions of the different serum samples, starting with a 1:400
dilution, were loaded onto the antigen-coated plates in the
blocking buffer and then incubated for 1 h at room
temperature. As a conjugate, rat monoclonal anti-mouse
IgG (Invitrogen) labelled with a horseradish peroxidase
was used at a 1:2000 dilution. Tetramethylbenzidine (BD
Bioscience) was used as a substrate. The reaction was
Mardanova et al. BMC Biotechnology  (2015) 15:42 Page 9 of 10monitored by measuring the OD at 450 nm. The endpoint
titres are defined as the highest dilution producing an OD
value twice that of the background (serum of non-
immunised mice).
Influenza viruses and challenge
The following mouse-adapted influenza viruses were used
to challenge animals immunised by the candidate vac-
cines: A/PR/8/34 (H1N1) at the dose of 10LD50 or 5LD50,
and A/Chicken/Kurgan/05/2005 (Н5N1) at the dose of
5LD50. The virus was administered intranasally in a total
volume of 100 μl to mice anaesthetised by ether. The mice
were monitored for weight loss and survival rate daily fol-
lowing the viral challenge for a period of 2 weeks. Survival
rate was determined by death or a cut-off of 25 % in body
weight loss at which point animals were euthanized.
Ethics statement
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of Animal Experimentation of the Research Institute of In-
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protein under reducing and nonreducing conditions.
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